ZURA Company Profile and Key Details

Wall Street analysts project EPS growth of -3.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $10.00. The high target offers 245.49% upside. The low target suggests 91.94% downside. The mean target is $13.43. This offers 157.77% upside. Zura Bio Limited earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 11, 2026, missed forecasts by 9.78%. The prior quarter beat by 29.41%. Over the last six quarters, Apple has recorded several small beats. These include 11.76% in May 08, 2025.

Short-term trend indicators are bearishly aligned (SMA20 8.72%, SMA50 21.66%, SMA200 114.89%). The stock’s 14-day RSI is 62.37 (firm momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.84% below its high and over 597.94% above its low. Average 10-day trading volume of 1.46 million shares is slightly above the 3-month average of 1.33 million, indicating heightened recent market interest.

Zura Bio Limited has 65.02 million shares outstanding. The public float is 37.88 million shares, elevated short interest at 0.72% of float. This equals 425.34 thousand shares. The short ratio is 1.15 days. Institutional investors hold 100.74% of the float. Insiders own 21.51%. AI Biotechnology LLC holds 6.55 million shares, Sidhu Someit has 2.09 million shares and Munshi Amit has 777.38 thousand shares.

The stock is currently mid-range between its 52-week high and low $1.88 and $7.44. With a market capitalization of about $494.94 million, Zura Bio Limited is classified as a small-cap and shows lower-than-market volatility (beta ~-0.04). Key stats such as the average daily volume over the past year has been around 1.33 million shares, in line with its 52-week average. Headquartered in Henderson, NV, Zura Bio Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sandeep C. Kulkarni, the company employs approximately 40 people and listed since March 21, 2023. Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases.

Zura Bio Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.16. This means the shares are trading above this model’s fair value.

Zura Bio Limited trades at a P/E ratio of -4.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.39 trading at moderately above to book value. The P/FCF stands at -6.45, also below market averages.

Our AI price prediction model suggests that Zura Bio Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.26%, with price expected at $5.38 by September 25, 2026, within a range of $5.15 to $5.61 3-Month Outlook: Projected rise of 58.93%, reaching $8.28 by December 10, 2026, with a range of $8.17 to $8.40. 1-Year Outlook: Projected gain of 358.16%, with price at $23.87 by September 10, 2027, within a range of $20.41 to $31.42.

Zura Bio Limited (NASDAQ:ZURA) shares are flat -4.39% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Zura Bio Limited trading at a premium to the broader market with a P/E of -4.66. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $12.06, suggesting 131.48% upside. Our AI forecast model points to short-term strength (3.26% over two weeks), a medium-term rise (58.93% over three months), and a longer-term gain (358.16% over one year), with expected trading ranges indicating moderate volatility.